German Court rules against Eli Lilly in vitamin regimen patent lawsuit The German Court of Appeal has ruled that Eli Lilly vitamin regimen patent for Alimta would not be infringed by a generic competitor that intends to market a dipotassium salt form of pemetrexed in Germany once the compound patent expires in December 2015. The German Court ruled in favor of the generic competitor in the case of Eli Lilly and Company v. Actavis. This decision vacated the prior decision of the Regional Court of Dusseldorf in April 2014. The compound patent for Alimta in Germany remains in force and is expected to provide exclusivity through December 2015.
Cowen to hold a conference 35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link